Apellis Pharmaceuticals Inc - Asset Resilience Ratio
Apellis Pharmaceuticals Inc (APLS) has an Asset Resilience Ratio of 0.58% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read APLS current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Apellis Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See APLS book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Apellis Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Apellis Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.75 Million | 0.58% |
| Total Liquid Assets | $4.75 Million | 0.58% |
Asset Resilience Insights
- Limited Liquidity: Apellis Pharmaceuticals Inc maintains only 0.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Apellis Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Apellis Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
Annual Asset Resilience Ratio for Apellis Pharmaceuticals Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Apellis Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.55% | $4.85 Million | $885.05 Million | +0.41pp |
| 2023-12-31 | 0.14% | $1.11 Million | $788.73 Million | -0.71pp |
| 2022-12-31 | 0.86% | $6.50 Million | $760.22 Million | -6.07pp |
| 2021-12-31 | 6.92% | $61.03 Million | $881.76 Million | -25.55pp |
| 2020-12-31 | 32.47% | $311.87 Million | $960.57 Million | -- |
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more